Open an account

Vivani Medical

VANI · NASDAQ

$1.12+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.12

About VANI

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Employees
42
Headquarters
Alameda, California
Listed
Dec 5, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
vivani.com

VANI key statistics

Market cap
101.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
147.50K
Volume
89.57K
Open price
$1.13
High today
$1.16
Low today
$1.11
52 Week high
$1.92
52 Week low
$0.9228

Vivani Medical (VANI) at a glance

As of Oct 20, 2026, Vivani Medical (VANI) shares are priced at $1.12, giving the company a market cap of 101.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.16. The current price is 0.9% above the day's low and 3.0% below its high.

Volume so far is 89.57K shares, below the average of 147.50K shares a day.

Over the past year Vivani Medical has ranged from $0.9228 to $1.92, and now sits 20% of the way up that range.

Vivani Medical met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.085.

The average analyst price target is $4.72, 321.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $4.72
Low
$3.54
Now
$1.12
High
$7.35

VANI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 6.9% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.1173
  2. Q4 FY24: reported -$0.11 per share against an estimate of -$0.1122
  3. Q1 FY25: reported -$0.11 per share against an estimate of -$0.1071
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.102
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.1122
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.102
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.0816
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.085

VANI news

  • Press releaseGlobe Newswire

    Why Investors Are Watching These Healthcare Movers

  • Press releaseBusiness Wire

    ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Vandana Singh

    EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data

  • Vandana Singh

    EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

  • Press releaseBusiness Wire

    Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

  • Press releaseBusiness Wire

    Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

  • Press releaseBusiness Wire

    Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

Similar companies

Companies in the same industry as Vivani Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.